Juvenile macular dystrophy, also known as juvenile macular degeneration, is a term used to describe a set of rare genetically inherited eye illnesses that can affect children and young adults. The macula of the eye deteriorates in juvenile macular dystrophy, although it is not the same as age-related macular degeneration (AMD). Juvenile macular dystrophy is an inherited condition that primarily affects the vision of children, teens, and young adults.
Juvenile macular degeneration is an inherited illness that causes irreversible visual loss in children during childhood and adolescence that is currently incurable. Stargardt disease is the most common kind of juvenile macular degeneration, affecting about 37,000 people in the United States and 66,000 in the European Union. There is no approved treatment for Stargardt patients at this time.
There has been an increase in the number of eye care centers, as primary eye care is being provided by optical shops. New optical shops have the most up-to-date technological gear that makes them more user-friendly. The availability of therapy has expanded as the number of optical shops, eye care clinics, and hospitals have increased.
During the forecast period, the global advancements in therapies in the juvenile macular degeneration treatment market are expected to be bolstered by increased R&D activities, an increase in the number of patients suffering from diseases, and the rapid expansion of health care and biopharmaceutical industries in developed and developing countries.
| Report Metric | Details |
| Market size available for years | 2023–2030 |
| Base year considered | 2023 |
| Forecast period | 2024–2030 |
| Forecast unit | Value (USD Million) |
| Segments covered | Type, End-user, and Region. |
| Regions covered | North America (the U.S. and Canada), Europe (UK, Germany, France, Italy, Spain, Russia, Rest of Europe), Asia-Pacific (China, India, Japan, Australia, South East Asia, Rest of Asia Pacific), Latin America and the Middle East and Africa (Brazil, Saudi Arabia, UAE, Rest of LAMEA) |
| Companies covered | Astellas Pharma Inc, Alkeus Pharmaceuticals, Inc., Biophytis SA, ProQR Therapeutics NV, Sanofi, Copernicus Therapeutics Inc, Generation Bio Corp, Grupo Ferrer Internacional SA, Katairo GmbH, WAVE Life Sciences Ltd, Lin Bioscience, Inc., Acucela Inc, Nightstar Therapeutics PLC, Ophthotech Corp, Spark Therapeutics Inc. |
Covid-19 Impact on Juvenile Macular Degeneration Treatment Market
In addition, the current Juvenile Macular Degeneration Treatment Market study offers a detailed analysis of the current COVID-19 pandemic impact on the market growth and its influence on the future growth of the Juvenile Macular Degeneration Treatment Market. The recently published report demonstrates the elevation in the demand for the healthcare sector. The healthcare manufacturers have experienced long term as well as short term effect which includes supply shortages, panic buying, and stocking, regulation changes as short-term whereas approval delays and possible trend variations in consumption could be perceived as long-term impacts of COVID-19 on the health and pharmaceutical market.
The increasing need for a cure has pushed vaccine research and manufacturers to the limit. In addition to this, panic conditions have already spurred the demand for many healthcare products and services which are discussed in detail in this report. Moreover, the impact of COVID-19 on overall market revenue for the base year 2020 and its projection up to 2027 is provided in detail in this report.
Juvenile Macular Degeneration Treatment Market Segment Overview
Based on Type, Stargardt’s disease is one of the important segments in the global Juvenile Macular Degeneration Treatment Market. Stargardt macular degeneration is a progressive vision loss condition caused by a genetic eye disorder. The retina, a specialized light-sensitive tissue that lines the back of the eye, is affected by this condition. Stargardt macular degeneration specifically affects the macula, a small area at the region of the eye.
Additionally, the global juvenile macular degeneration treatment market can be divided into three types of end-users: hospitals, ophthalmic clinics, and ambulatory surgical centers. The global macular degeneration treatment market was dominated by the hospital segment. During the projected period, the segment is expected to maintain its leading position. A big portion of the public prefers to seek treatment in a hospital rather than an ophthalmic clinic because hospital therapy is less expensive. For the treatment of AMD, an ambulatory surgical facility is a less favoured choice.
Juvenile Macular Degeneration Treatment Market, By Type
· Stargardt’s disease
· Best Disease
· Juvenile Retinoschisis
Juvenile Macular Degeneration Treatment Market, By End-user
· Hospitals
· Ophthalmic clinics
· Ambulatory surgical centers
Juvenile Macular Degeneration Treatment Market Regional Overview
The global juvenile macular degeneration treatment market can be divided into five primary regions based on geography: North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa. North America and Europe are likely to account for the majority of the global juvenile macular degeneration treatment market throughout the forecast period, owing to the developed healthcare infrastructure and high patient population in these regions, as well as growing technological advancement. Increased government participation in emerging markets has resulted in increased disease awareness and better healthcare infrastructure. In addition, rising economies such as Asia, Africa, and Latin America have had socioeconomic development. These variables contribute to the population's general improvement in spending capability. Furthermore, these countries have seen an increase in foreign direct investment. As a result, several foreign players are now entering these markets.
Juvenile Macular Degeneration Treatment Market, By Geography
· North America (US & Canada)
· Europe (UK, Germany, France, Italy, Spain, Russia & Rest of Europe)
· Asia-Pacific (Japan, China, India, Australia, & South Korea, & Rest of Asia-Pacific)
· LAMEA (Brazil, Saudi Arabia, UAE & Rest of LAMEA)
Juvenile Macular Degeneration Treatment Market, Key Players
· Astellas Pharma Inc
· Alkeus Pharmaceuticals, Inc.
· Biophytis SA
· ProQR Therapeutics NV
· Sanofi
· Copernicus Therapeutics Inc
· Generation Bio Corp
· Grupo Ferrer Internacional SA
· Katairo GmbH
· WAVE Life Sciences Ltd
· Lin Bioscience, Inc.
· Acucela Inc
· Nightstar Therapeutics PLC
· Ophthotech Corp
· Spark Therapeutics Inc
Frequently Asked Questions (FAQ) :
Q1. What are the driving factors for the global Juvenile Macular Degeneration Treatment market?
Q2. Which Segments are covered in the global Juvenile Macular Degeneration Treatment market report?
Q3. Which segment is projected to hold the largest share in the global Juvenile Macular Degeneration Treatment market.?
Q4. Which region holds the largest share in the global Juvenile Macular Degeneration Treatment market?
Q5. Which are the prominent players in the global Juvenile Macular Degeneration Treatment market?
1. Introduction
- 1.1. Research Scope
- 1.2. Market Segmentation
- 1.3. Research Methodology
- 1.4. Definitions and Assumptions
2. Executive Summary
3. Market Dynamics
- 3.1. Market Drivers
- 3.2. Market Restraints
- 3.3. Market Opportunities
4. Key Insights
- 4.1. Key Emerging Trends – For Major Countries
- 4.2. Latest Technological Advancement
- 4.3. Regulatory Landscape
- 4.4. Industry SWOT Analysis
- 4.5. Porters Five Forces Analysis
5. Global Juvenile Macular Degeneration Treatment Market Analysis (USD Billion), Insights and Forecast, 2020-2027
- 5.1. Key Findings / Summary
- 5.2. Market Analysis, Insights and Forecast – By Type
- 5.2.1. Stargardt’s disease
- 5.2.2. Best Disease
- 5.2.3. Juvenile Retinoschisis
- 5.3. Market Analysis, Insights and Forecast – By End-user
- 5.3.1. Hospitals
- 5.3.2. Ophthalmic clinics
- 5.3.3. Ambulatory surgical centers
- 5.4. Market Analysis, Insights and Forecast – By Region
- 5.4.1. North America
- 5.4.2. Europe
- 5.4.3. Asia Pacific
- 5.4.4. Latin America, Middle East and Africa
6. North America Juvenile Macular Degeneration Treatment Market Analysis (USD Billion), Insights and Forecast, 2020-2027
- 6.1. Key Findings / Summary
- 6.2. Market Analysis, Insights and Forecast – By Type
- 6.2.1. Stargardt’s disease
- 6.2.2. Best Disease
- 6.2.3. Juvenile Retinoschisis
- 6.3. Market Analysis, Insights and Forecast – By End-user
- 6.3.1. Hospitals
- 6.3.2. Ophthalmic clinics
- 6.3.3. Ambulatory surgical centers
- 6.4. Market Analysis, Insights and Forecast – By Country
- 6.4.1. U.S.
- 6.4.2. Canada
7. Europe Juvenile Macular Degeneration Treatment Market Analysis (USD Billion), Insights and Forecast, 2020-2027
- 7.1. Key Findings / Summary
- 7.2. Market Analysis, Insights and Forecast – By Type
- 7.2.1. Stargardt’s disease
- 7.2.2. Best Disease
- 7.2.3. Juvenile Retinoschisis
- 7.3. Market Analysis, Insights and Forecast – By End-user
- 7.3.1. Hospitals
- 7.3.2. Ophthalmic clinics
- 7.3.3. Ambulatory surgical centers
- 7.4. Market Analysis, Insights and Forecast – By Country
- 7.4.1. UK
- 7.4.2. Germany
- 7.4.3. France
- 7.4.4. Italy
- 7.4.5. Spain
- 7.4.6. Russia
- 7.4.7. Rest of Europe
8. Asia Pacific Juvenile Macular Degeneration Treatment Market Analysis (USD Billion), Insights and Forecast, 2020-2027
- 8.1. Key Findings / Summary
- 8.2. Market Analysis, Insights and Forecast – By Type
- 8.2.1. Stargardt’s disease
- 8.2.2. Best Disease
- 8.2.3. Juvenile Retinoschisis
- 8.3. Market Analysis, Insights and Forecast – By End-user
- 8.3.1. Hospitals
- 8.3.2. Ophthalmic clinics
- 8.3.3. Ambulatory surgical centers
- 8.4. Market Analysis, Insights and Forecast – By Country
- 8.4.1. China
- 8.4.2. India
- 8.4.3. Japan
- 8.4.4. Australia
- 8.4.5. South East Asia
- 8.4.6. Rest of Asia Pacific
9. Latin America, Middle East and Africa Juvenile Macular Degeneration Treatment Market Analysis (USD Billion), Insights and Forecast, 2020-2027
- 9.1. Key Findings / Summary
- 9.2. Market Analysis, Insights and Forecast – By Type
- 9.2.1. Stargardt’s disease
- 9.2.2. Best Disease
- 9.2.3. Juvenile Retinoschisis
- 9.3. Market Analysis, Insights and Forecast – By End-user
- 9.3.1. Hospitals
- 9.3.2. Ophthalmic clinics
- 9.3.3. Ambulatory surgical centers
- 9.4. Market Analysis, Insights and Forecast – By Country
- 9.4.1. Brazil
- 9.4.2. Saudi Arabia
- 9.4.3. UAE
- 9.4.4. Rest of LAMEA
10. Competitive Analysis
- 10.1. Company Market Share Analysis, 2018
- 10.2. Key Industry Developments
- 10.3. Company Profile
- 10.4. Astellas Pharma Inc
- 10.4.1. Business Overview
- 10.4.2. Segment 1 & Service Offering
- 10.4.3. Overall Revenue
- 10.4.4. Geographic Presence
- 10.4.5. Recent Development
- 10.5. Alkeus Pharmaceuticals, Inc.
- 10.6. Biophytis SA
- 10.7. ProQR Therapeutics NV
- 10.8. Sanofi
- 10.9. Copernicus Therapeutics Inc
- 10.10. Generation Bio Corp
- 10.11. Grupo Ferrer Internacional SA
- 10.12. Katairo GmbH
- 10.13. WAVE Life Sciences Ltd
- 10.14. Lin Bioscience, Inc.
- 10.15. Acucela Inc
- 10.16. Nightstar Therapeutics PLC
- 10.17. Ophthotech Corp
Data Library Research are conducted by industry experts who offer insight on industry structure, market segmentations technology assessment and competitive landscape (CL), and penetration, as well as on emerging trends. Their analysis is based on primary interviews (~ 80%) and secondary research (~ 20%) as well as years of professional expertise in their respective industries. Adding to this, by analysing historical trends and current market positions, our analysts predict where the market will be headed for the next five years. Furthermore, the varying trends of segment & categories geographically presented are also studied and the estimated based on the primary & secondary research.
In this particular report from the supply side Data Library Research has conducted primary surveys (interviews) with the key level executives (VP, CEO’s, Marketing Director, Business Development Manager and SOFT) of the companies that active & prominent as well as the midsized organization
FIGURE 1: DLR RESEARH PROCESS
Extensive primary research was conducted to gain a deeper insight of the market and industry performance. The analysis is based on both primary and secondary research as well as years of professional expertise in the respective industries.
In addition to analysing current and historical trends, our analysts predict where the market is headed over the next five years.
It varies by segment for these categories geographically presented in the list of market tables. Speaking about this particular report we have conducted primary surveys (interviews) with the key level executives (VP, CEO’s, Marketing Director, Business Development Manager and many more) of the major players active in the market.
Secondary ResearchSecondary research was mainly used to collect and identify information useful for the extensive, technical, market-oriented, and Friend’s study of the Global Extra Neutral Alcohol. It was also used to obtain key information about major players, market classification and segmentation according to the industry trends, geographical markets, and developments related to the market and technology perspectives. For this study, analysts have gathered information from various credible sources, such as annual reports, sec filings, journals, white papers, SOFT presentations, and company web sites.
Market Size EstimationBoth, top-down and bottom-up approaches were used to estimate and validate the size of the Global market and to estimate the size of various other dependent submarkets in the overall Extra Neutral Alcohol. The key players in the market were identified through secondary research and their market contributions in the respective geographies were determined through primary and secondary research.
Forecast Model
